Related Experiment Videos
Implications of the clinical trials on the management of hypertension
Insights
Diuretic treatment significantly reduces cardiovascular events and stroke deaths in hypertensive patients. Effective blood pressure lowering also decreases ischemic heart disease mortality, especially in the elderly and those with target-organ involvement.
Area of Science:
- Cardiology
- Clinical Trials
- Pharmacology
Background:
- Hypertension is a major risk factor for cardiovascular events.
- Diuretics are commonly used as first-line therapy for hypertension.
- Previous studies have investigated the efficacy of diuretics in reducing cardiovascular outcomes.
Purpose of the Study:
- To evaluate the impact of diuretic therapy on cardiovascular events and mortality in hypertensive patients.
- To assess the benefits of blood pressure lowering in specific patient subgroups.
Main Methods:
- Systematic review of major clinical trials using diuretics for hypertension.
- Analysis of data from studies including the Hypertension Detection and Follow-up Program and the European Working Party on Hypertension in the Elderly.
- Stratification of results based on initial diastolic blood pressure and presence of target-organ involvement.
Main Results:
- Diuretics demonstrated a marked reduction in overall cardiovascular events and stroke deaths.
- Benefits were observed in patients with diastolic pressures ≥95 mm Hg, and also in those with pressures of 90-95 mm Hg.
- Reduced ischemic heart disease mortality was reported in elderly patients and those with target-organ involvement.
Conclusions:
- Diuretic therapy is effective in reducing major cardiovascular events and stroke deaths.
- Effective blood pressure control through diuretics offers significant long-term benefits, including reduced cardiovascular mortality.
- Pharmacological intervention with diuretics is justified when non-drug treatments are insufficient.
Abstract:
All of the major clinical trials that employed diuretics as initial monotherapy or as one of several first-step drugs have demonstrated a marked reduction in overall cardiovascular events and stroke deaths in treated patients. Benefit has been demonstrated in all trials in patients with initial diastolic pressures of 95 mm Hg or above and in the Hypertension Detection and Follow-up Program, the only study to test the hypothesis, benefit of treatment was noted in patients with pretreatment diastolic pressures of 90 to 95 mm Hg. Although several of the trials failed to show a significant decrease in coronary events in treated patients, the two studies (Hypertension Detection and Follow-up Program and European Working Party on Hypertension in the Elderly) that treated either elderly patients or patients with pretreatment target-organ involvement, reported a reduction in deaths from ischemic heart disease following effective lowering of blood pressure. The long-term benefits of effective treatment of hypertension appear to justify the use of pharmacological intervention if nondrug treatment proves ineffective.